Boston Scientific price target raised to $100 from $85 at Stifel

Stifel analyst Rick Wise raised the firm’s price target on Boston Scientific (BSX) to $100 from $85 and keeps a Buy rating on the shares. Boston Scientific’s OPTION trial, which is set to read-out November 15 at AHA 2024, presents a “meaningful” left-atrial-appendage-closure, or LAAC, device addressable market expansion and sales growth acceleration opportunity, the analyst tells investors. After having surveyed another thirty electrophysiologists and as well having three in-depth physician conversations to better frame “how much” and “how quickly” positive OPTION data might impact WATCHMAN growth, the firm found that physicians consulted broadly expect OPTION to meet its primary endpoints, that majority of those physicians anticipate OPTION will directly accelerate procedure volumes and that positive data should accelerate LAAC volumes quickly, the analyst reported.